132 Annual Meeting Logo - Go to APHA Meeting Page  
APHA Logo - Go to APHA Home Page

Introduction to buprenorphine and office-based opioid addiction therapy under the new paradigm established by the Drug Addiction Treatment Act of 2000

Wayne Brandes, DO, American Institutes for Research, 10720 Columbia Pike, Suite 500, Silver Spring, MD 20901, 301-592-2163, kcyr@air.org

This session will provide an introduction to opioid addiction treatment under the new clinical and regulatory model established by the Drug Addiction Treatment Act of 2000 (DATA 2000). DATA 2000 allows qualified physicians, for the first time in more than 90 years, to dispense or prescribe approved Schedule III, IV, and V opioid medications for the treatment of opioid addiction outside of the context of the traditional Opioid Treatment Program setting. On October 8, 2002, two new formulations of the Schedule III opioid partial agonist medication buprenorphine (Suboxone® and Subutex®) became the first pharmaceuticals to receive FDA approval for use under the DATA 2000 paradigm. This new treatment paradigm promises to bring opioid addiction therapy into the mainstream of medical care, thereby greatly increasing utilization and access to care and helping to close the “treatment gap.”

Learning Objectives:

Related Web page: buprenorphine.samhsa.gov

Presenting author's disclosure statement:
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.

Fighting the Good Fight: Opioids and Buprenorphine

The 132nd Annual Meeting (November 6-10, 2004) of APHA